ABITRAM: A Potential Drug Target for Alzheimer's (G54942)

Target Name: ABITRAM

NCBI ID: G54942

ABITRAM

ABITRAM: A Potential Drug Target for Alzheimer's

ABITRAM (Alzheimer's disease-associated intracellular signaling protein 8) is a protein that is expressed in the brain and has been associated with the development and progression of Alzheimer's disease (AD). The protein is known to play a role in the intracellular signaling pathway, which is a system that regulates the flow of information within cells.

Recent studies have identified ABITRAM as a potential drug target for the treatment of AD. By blocking the activity of ABITRAM, researchers have found that they can reduce the formation of beta-amyloid plaques, a hallmark of AD, and improve memory and other cognitive functions in AD patients.

ABITRAM is also a biomarker for the early detection of AD. The protein is expressed in the brain at high levels in people with AD, and levels are typically lower in individuals without the disease. This makes ABITRAM a promising biomarker for the disease, and researchers are currently exploring its potential as a diagnostic tool.

One of the reasons why ABITRAM is considered a potential drug target is its role in the intracellular signaling pathway. The pathway is responsible for transmitting information from the cell's surface to its internal environment, and it is critical for the regulation of many important cellular processes.

Research has shown that ABITRAM is involved in the regulation of several key intracellular signaling pathways, including the TGF-beta pathway, the Wnt pathway, and the Notch pathway. These pathways are involved in the development and maintenance of the brain, and are thought to be involved in the development of AD.

In addition to its role in intracellular signaling, ABITRAM is also involved in the regulation of inflammation. Studies have shown that ABITRAM is involved in the regulation of the immune response, and that it plays a role in the regulation of inflammation in the brain.

This is potentially important for the development of AD because inflammation is thought to play a role in the development and progression of the disease. By targeting ABITRAM, researchers may be able to reduce inflammation in the brain and improve the risk of AD.

Another potential mechanism by which ABITRAM may contribute to the development of AD is its role in the regulation of the blood-brain barrier. The blood-brain barrier is a specialized barrier that separates the brain from the bloodstream, and it is responsible for the delivery of important nutrients and oxygen to the brain.

Research has shown that ABITRAM is involved in the regulation of the blood-brain barrier, and that it plays a role in the delivery of nutrients and oxygen to the brain. This is potentially important for the development of AD because a compromised blood-brain barrier can contribute to the progression of the disease.

In conclusion, ABITRAM is a protein that is associated with the development and progression of Alzheimer's disease. Its role in the intracellular signaling pathway, inflammation, and blood-brain barrier suggests that it may be a promising drug target for the treatment of AD. Further research is needed to fully understand the role of ABITRAM in the disease and its potential as a diagnostic tool.

Protein Name: Actin Binding Transcription Modulator

Functions: Actin-binding protein that regulates actin polymerization, filopodia dynamics and increases the branching of proximal dendrites of developing neurons

The "ABITRAM Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ABITRAM comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets